Trial · NCT01589302
Results by group62
Each measurement the trial posted, group by group, in the words and numbers it posted.
41 to 60 of 62
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Neutrophil Count Decreased | 40 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Platelet Count Decreased | 8 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | White Blood Cell Decreased | 10 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Hyperuricemia | 4 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Hypophosphatemia | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Arthralgia | 2 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Arthritis | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Hematuria | 2 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Hypoxia | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Respiratory Failure | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Rash Maculo-papular | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Hematoma | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Hypertension | 7 | patients | |
| Resistance Studies of Ibrutinib | Treatment (Ibrutinib) | 13.2 | 95% Confidence Interval 8.2 to 19.6 | percentage of patients | |
| Effectiveness of Ibrutinib Bridging Patients to Allogeneic Stem Cell Transplant and Outcome of Patients Following This Intervention | Treatment (Ibrutinib) | 1 | participants | ||
| Cancer-Specific Stress as Measured by the Impact of Event Scale-Revised (IES-R) | Treatment (Ibrutinib) | 9.18 | Standard Deviation 8.35 | units on a scale | |
| Cognitive-Affective Depressive Symptoms as Measured by the Beck Depression Inventory-2nd Edition (BDI-II) | Treatment (Ibrutinib) | 1.88 | Standard Deviation 3.11 | units on a scale | |
| Negative Mood Quality of Life Measured by a 37-item Questionnaire | Treatment (Ibrutinib) | 0.89 | Standard Deviation 18.12 | units on a scale | |
| Mental Health Quality of Life Was Measured by the Mental Component Summary Score of the Medical Outcomes Study | Treatment (Ibrutinib) | 53.98 | Standard Deviation 8.72 | units on a scale | |
| Fatigue Symptom Inventory (FSI) Interference Quality of Life as Measured by a 11-item Total Disruption Index Sub Scale of Fatigue Symptoms Inventory | Treatment (Ibrutinib) | 9.70 | Standard Deviation 13.11 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01589302/results?page=3